Burney Co. Sells 2,151 Shares of Eli Lilly and Company (NYSE:LLY)

Burney Co. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,465 shares of the company’s stock after selling 2,151 shares during the quarter. Eli Lilly and Company comprises approximately 1.2% of Burney Co.’s portfolio, making the stock its 11th biggest holding. Burney Co.’s holdings in Eli Lilly and Company were worth $31,204,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Private Client Services LLC lifted its holdings in Eli Lilly and Company by 2.3% during the 2nd quarter. Private Client Services LLC now owns 981 shares of the company’s stock worth $888,000 after purchasing an additional 22 shares in the last quarter. HB Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 7.1% in the second quarter. HB Wealth Management LLC now owns 41,460 shares of the company’s stock worth $37,537,000 after buying an additional 2,745 shares in the last quarter. Significant Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 22.1% in the second quarter. Significant Wealth Partners LLC now owns 559 shares of the company’s stock valued at $506,000 after acquiring an additional 101 shares during the period. Valley Brook Capital Group Inc. grew its stake in Eli Lilly and Company by 7.8% during the second quarter. Valley Brook Capital Group Inc. now owns 1,464 shares of the company’s stock valued at $1,325,000 after acquiring an additional 106 shares in the last quarter. Finally, Wright Investors Service Inc. increased its holdings in Eli Lilly and Company by 28.3% during the 2nd quarter. Wright Investors Service Inc. now owns 3,689 shares of the company’s stock worth $3,340,000 after acquiring an additional 813 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.7 %

Shares of LLY traded down $7.03 during trading hours on Thursday, hitting $941.91. The company had a trading volume of 970,967 shares, compared to its average volume of 3,068,266. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The stock’s 50 day moving average price is $888.89 and its 200 day moving average price is $818.23. The firm has a market cap of $895.20 billion, a P/E ratio of 139.62, a P/E/G ratio of 1.81 and a beta of 0.41.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.55%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,120,089 shares of company stock worth $990,278,343. 0.13% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on LLY. Guggenheim raised their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Barclays upped their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, Argus lifted their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Two research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $961.76.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.